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Sex-specific effects of microbiome perturbations on
cerebral Ab amyloidosis and microglia phenotypes
Hemraj B. Dodiya1, Thomas Kuntz1, Shabana M. Shaik1, Caroline Baufeld2, Jeffrey Leibowitz2, Xulun Zhang1, Neil Gottel3, Xiaoqiong Zhang1,
Oleg Butovsky2, Jack A. Gilbert3, and Sangram S. Sisodia1
We demonstrated that an antibiotic cocktail (ABX)-perturbed gut microbiome is associated with reduced amyloid-b (Ab)
plaque pathology and astrogliosis in the male amyloid precursor protein (APP)SWE/presenilin 1 (PS1)ΔE9 transgenic model of Ab
amyloidosis. We now show that in an independent, aggressive APPSWE/PS1L166P (APPPS1-21) mouse model of Ab amyloidosis,
an ABX-perturbed gut microbiome is associated with a reduction in Ab pathology and alterations in microglial morphology,
thus establishing the generality of the phenomenon. Most importantly, these latter alterations occur only in brains of male
mice, not in the brains of female mice. Furthermore, ABX treatment lead to alterations in levels of selected microglial
expressed transcripts indicative of the “M0” homeostatic state in male but not in female mice. Finally, we found that
transplants of fecal microbiota from age-matched APPPS1-21 male mice into ABX-treated APPPS1-21 male restores the gut
microbiome and partially restores Ab pathology and microglial morphology, thus demonstrating a causal role of the
microbiome in the modulation of Ab amyloidosis and microglial physiology in mouse models of Ab amyloidosis.
Introduction
Alzheimer’s disease (AD), the most common age-associated
chronic progressive neurodegenerative disorder, is pathologi-
cally characterized by the extracellular deposition of amyloid-β
(Aβ) peptides in senile plaques and the intracellular accumula-
tion of hyperphosphorylated tau protein in neurofibrillary tan-
gles. In addition, positron emission tomography studies showed
that activated microglia and neuroinflammation are highly
correlated with cognitive decline in AD patients (Cagnin et al.,
2001; Hamelin et al., 2016). Furthermore, genome-wide associ-
ation studies have identified numerous polymorphisms within
genes critical for innate immune responses (i.e., CD33 and
TREM-2) that confer an elevated risk of late-onset AD (Griciuc
et al., 2013; Guerreiro et al., 2013; Naj et al., 2014; Efthymiou and
Goate, 2017). It is now well established that neuroinflammation,
instead of being simply a bystander that is activated by central
stimuli (such as senile plaques and neurofibrillary tangles;
Heneka et al., 2015) and peripheral stimuli (such as endotoxins;
Wendeln et al., 2018), plays an important role in AD
pathogenesis.
Recent evidence suggests that intestinal microbiota could
play a major role in peripheral as well as central immune
activation and inflammation in various neurological condi-
tions including autism spectrum disorders, multiple sclerosis,
Parkinson’s disease, and AD (Cryan and O’Mahony, 2011;
Sherwin et al., 2018). Specifically, patients with cogni-
tive impairment and brain amyloidosis exhibit altered gut
microbiota, which in turn was significantly associated with
pro-inflammatory cytokine gene profiles in the blood of these
subjects (Cattaneo et al., 2017). In this regard, other studies have
reported decreased Firmicutes, increased Bacteroidetes, and
decreased Bifidobacterium in AD subjects (Vogt et al., 2017;
Zhuang et al., 2018). Besides these human studies, microbiome
changes have also been reported in transgenic (Tg) mouse
models of Aβ amyloidogenesis (Brandscheid et al., 2017; Shen
et al., 2017; Ba¨uerl et al., 2018). More recently, Harach et al.
(2017) demonstrated that germ-free (GF) APPPS1-21 Tg mice
that express familial AD–linked APPSWE and PS1L166P transgenes
driven by the neuron-specific Thy1 promoter (Radde et al., 2006)
exhibit reduced Aβ deposition in the brain compared with their
specific pathogen-free counterparts (Harach et al., 2017). Im-
portantly, we have documented that in the APPSWE/PS1ΔE9
mouse model of Aβ amyloidosis, postnatal and long-term anti-
biotic cocktail (ABX) administration in male mice leads to re-
duced Aβ deposition and associated gliosis (Minter et al., 2016,
2017) and that long-term ABX treatment leads to reductions in
Aβ deposition selectively in males but not in females (Minter
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et al., 2016). While these studies collectively establish a strong
link between the gut microbiome and AD pathogenesis, the
mechanism(s) by which microbial alterations impact on patho-
genesis remain silent.
Several investigations of the microbiome-gut-brain axis have
shown that the microbiome plays a critical role in the develop-
ment of brain circuitry, neurophysiology, behavior, and most
importantly, the physiology of brain microglial cells (Diaz Heijtz
et al., 2011; Braniste et al., 2014; Sharon et al., 2016). Microglia,
also known as “the resident macrophages of the brain,” consti-
tute the first line of defense against injury and infection. Mi-
croglia also contribute to brain development throughout
embryonic and adult life by regulating aspects of synaptic
transmission, synapse formation and pruning, cell death, cell
survival, and embryonic brain wiring (Schafer and Stevens,
2015; Hong et al., 2016; Ransohoff and El Khoury, 2016;
Reemst et al., 2016; Tay et al., 2017). The gut microbiome is an
important environmental cue for microglial function in immune
and neuronal responses throughout the host’s life span. In this
regard, microglia respond to environmental challenges in a sex-
and time-dependent manner beginning at prenatal stages (Thion
et al., 2018), and significant differences in the transcriptomes of
microglia obtained from adult male versus female mice have
been documented (Villa et al., 2018). Furthermore, microglial
maturation and function are impaired both in the absence of the
microbiome in GF or ABX-treated mice (Erny et al., 2015;
Matcovitch-Natan et al., 2016). For example, microglial cells in
GF and ABX-treated mice display significantly altered inflam-
matory gene expression profiles that influence their surveil-
lance function that is accompanied by altered cellular
morphologies (Erny et al., 2015).
To these aforementioned aspects of microbiome-mediated
effects on microglial homeostasis, clinical and preclinical stud-
ies have revealed that sex has a major impact on a wide range of
autoimmune disorders (i.e., females are 2–10 times more sus-
ceptible than males; Zandman-Goddard et al., 2007; Fish, 2008).
In this regard, while sex-specific differences in Aβ burden and
tauopathy are not apparent in the brains of aged individuals and
AD patients, sex differences in the clinical phenotype and pro-
gression of AD have beenwell documented (Scheinin et al., 2014;
Gottesman et al., 2016; Johnson et al., 2016; Jack et al., 2017;
Vemuri et al., 2017; Cavedo et al., 2018).
While compelling, our published studies on the role of the gut
microbiome on Aβ amyloidosis in male mice (Minter et al., 2016,
2017) was limited to assessments in a single strain of mice,
namely, the amyloid precursor protein (APP)SWE/presenilin
1 (PS1)ΔE9 mouse model (Jankowsky et al., 2002) in which ex-
pression of cDNA encoding familial AD–linked human APPSWE
and PS1ΔE9 variants are transcriptionally driven by the ubiqui-
tously expressed mouse prion protein promoter. In view of
potential caveats associated with transgene insertion and mis-
and/or overexpression of the prion protein promoter-driven
transgenes, we examined the impact of long-term ABX treat-
ment in male and female APPPS1-21 mice that exhibit Aβ amy-
loidosis by the age of 6–7 wk (Radde et al., 2006). Confirming
our earlier findings, we now report that long-term ABX treat-
ment resulted in reductions of Aβ deposition and microglial
morphological alterations in male but not female APPPS1-21
mice. Transcriptomic profiling revealed that males exhibited
profound changes in microglial gene expression compared with
ABX-treated femalemice. Finally, transplants of fecal microbiota
from age-matched APPPS1-21 male mice into ABX-treated male
mice partially restored Aβ amyloidosis and microglial pheno-
types that are observed in vehicle-treated APPPS1-21 mice.
Collectively, our studies reveal that in two independent Tg
mouse models of Aβ amyloidosis ABX-mediated microbiome
perturbations influence brain Aβ amyloidosis and microglial
homeostasis in a sex-specific manner.
Results
Thy1 promoter-driven APPSWE/PS1L166P transgenes are
selectively expressed in the brain
To assess the tissue-level expression of human APPswe in the Tg
mouse line, we performed Western blot analysis of detergent-
soluble extracts using the human APP-specific 6E10 antibody.
These studies revealed that in 4- to 5-mo-old APPPS1-21 mice,
human APPswe is expressed selectively in the brain (Fig. S1,
lanes 3 and 4), while in 8-mo-old APPSWE/PS1ΔE9 Tg mice,
APPswe is expressed both in the brain and in a variety of sam-
pled peripheral tissues (Fig. S1), as previously described
(Jankowsky et al., 2002). Importantly, Aβ peptides are only de-
tectable in extracts prepared from the brains of either mouse
line (Fig. S1, lanes 1–4).
Postnatal antibiotic treatment results in similar microbiome
changes in male and female APPPS1-21 mice at postnatal day
(P) 22
The fecal microbiota at P22 was evaluated by using Illumina
MiSeq amplicon sequencing. The β diversity differences be-
tween bacterial communities found in the vehicle- and ABX-
treated groups were calculated with the weighted UniFrac
metric and visualized by principal coordinate analysis (PCoA).
Microbial β diversity was significantly different between vehi-
cle- and ABX-treated groups and showed clear clustering by
using PCoA (Fig. S2 A). There was no significant difference in β
diversity between male and female samples, but there was sig-
nificantly reduced richness and evenness in ABX-treated males
and ABX-treated females compared with their vehicle-treated
counterparts (Fig. S2, B and C).
Analysis of composition of microbiomes (ANCOM) analyses
of 16S ribosomal RNA (rRNA) sequencing data at the DADA2
inferred exact sequence variant (ESV) level (taxonomy assigned
via GreenGenes) and clustered species levels were performed to
determine the taxa that described the most variance between
groups. Vehicle-treated male and female mice showed no dif-
ferences at P22. Likewise, ABX-treated mice did not differ sig-
nificantly in ESVs or species by sex. However, as expected, ABX
treatment showed significant changes in microbial composition
in both sexes (Table S1) compared with their respective vehicle
controls.
Similarly, as anticipated, predicted metagenome analysis
through Phylogenetic Investigation of Communities by Recon-
struction of Unobserved States (PICRUSt) showed significant
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differences in many pathways between ABX-treated male and
female mice compared with their vehicle-treated counterparts
(Table 1), and there were no significant differences between
male and female mice irrespective of the vehicle or ABX treat-
ments. Taken together, these data indicate that the microbiome
changes in both male and female mice after P14–P21 ABX gavage
are highly comparable.
Long-term ABX treatment results in sex-specific microbiome
changes in APPPS1-21 mice at the time of cull
It is well documented that ABX treatment results in cecum en-
largement (Savage and Dubos, 1968; Minter et al., 2016). To con-
firm this finding in our mice, we showed that at the time of cull,
ABX-treated male and female APPPS1-21 mice exhibited larger
ceca compared with the vehicle-treated controls (Fig. S2 D). Cecal
weight analyses showed significantly larger ceca in ABX-treated
male compared with vehicle-treated male mice, in ABX-treated
female compared with vehicle-treated female mice, and ABX-
treated male compared with ABX-treated female mice (Fig. S2 E).
Amplicon sequencing was performed to analyze the fecal
microbiota in mice at necropsy. As before, microbial β diversity
at 7 wk was significantly different between ABX-treated mice
and their vehicle-treated counterparts (Fig. 1 A), but no signif-
icant differences were observed for male versus female groups.
We observed significantly reduced diversity in ABX-treated
male and ABX-treated female mice compared with their
vehicle-treated counterparts (Fig. 1, B and C).
ANCOM comparison of ESVs and clustered species at 7 wk
again showed large numbers of taxa whose proportions were
significantly different between vehicle- and ABX-treated groups
in both males and females (Table 2) with some overlapping
features. Among ABX-treated mice, an Akkermansia muciniphila
ESV and an Allobaculum spp. cluster were significantly enriched
in females compared with males. In vehicle-treated mice, a
Mollicutes RF39 ESV was significantly enriched in males.
As expected, PICRUSt showed significant differences inmany
pathways between ABX-treated male and female mice compared
with their vehicle-treated controls and between ABX-treated
male and ABX-treated female mice but not between vehicle-
treated male and vehicle-treated female mice (Table 1). Pro-
inflammatory pathways, such as bacterial secretion system,
bacterial toxins, lipopolysaccharide biosynthesis, and lipopoly-
saccharide synthesis protein, were significantly enriched in
ABX-treated female compared with ABX-treated male mice. In
this regard, higher levels of microbial endotoxins could affect
the peripheral and central inflammatory processes as has been
shown recently (Wendeln et al., 2018). Collectively, these data
indicate that long-term ABX treatment results in distinct mi-
crobiome changes in both male and female APPPS1-21 mice at
7 wk of age and that ABX-treated female mice exhibit an en-
richment of pro-inflammatory metabolic pathways compared
with ABX-treated male mice.
Long-term ABX treatment results in sex-specific alterations of
circulating inflammatory mediators in APPPS1-21 mice
It is well established that the commensal bacteria can modulate
the peripheral innate immune system (Lathrop et al., 2011) and
impact cytokine production (Fung et al., 2016). We quantified
the levels of 62 circulating cytokines and chemokines in the
plasma samples of the vehicle- and ABX-treated mice using
commercially available cytokine array membrane kits. Numer-
ous cytokines were altered with ABX-treatment, and this pat-
tern was different in ABX-treated male versus female mice (Fig.
S3, A and B). ABX-treated male mice exhibited elevated levels of
anti-inflammatory/neuroprotective factors, including insulin-
like growth factor binding protein 3, Interleukin 6 (IL-6), and
IL-10, and decreased levels of pro-inflammatory cytokines/
chemokines, including Eotaxin1, IL-1B, IL-2, IL-3, IL-17A, and
RANTES (Regulated upon Activation, Normal T cell Expressed,
and Secreted; also known as Chemokine [C-C motif] ligand 5
[CCL5]), relative to vehicle-treated controls. In contrast, ABX-
treated female mice showed up-regulation of pro-inflammatory
cytokines/chemokines, including IL-1B, IL-5, IL-9, and IL-17A.
Importantly, ABX-treated female mice exhibited elevated levels
of pro-inflammatory cytokines/chemokines, such as CCL11 (Eo-
taxin1; 7.11-fold), IL-1B (6.92-fold), IL-2 (6.35-fold), IL-3 (7.01-
fold), IL-5 (7.32-fold), IL-9 (8.51-fold), and IL-17A (7.44-fold),
relative to ABX-treated male mice. Moreover, ABX-treated fe-
male mice also exhibited decreased levels of IL-12 (11.16-fold),
chemokine (C-X-C motif) ligand 1 (CXCL1; also known as KC;
13.02-fold), and P-selectin (11.94-fold) cytokines/chemokines
compared with ABX-treated male mice. These findings suggest
that the long-term ABX-altered microbiome has distinct effects
on the circulating chemokines and cytokines in a sex-specific
manner with female mice exhibiting higher levels of pro-
inflammatory mediators.
Long-term ABX treatment results in reduced Ab deposition
only in male APPPS1-21 mice
To investigate the effect of long-term ABX treatment on Aβ
amyloidosis in APPPS1-21 mice, we sacrificed animals at 7 wk of
age. Using Aβ-specific monoclonal antibody 3D6, we confirmed
that Aβ deposition is prominent in the cortex, with negligible
levels in the hippocampus (Radde et al., 2006; Fig. 2 A). ABX-
treated male APPPS1-21 animals exhibited significantly reduced
cortical Aβ burden compared with vehicle-treated male mice.
Notably, vehicle-treated female mice showed significantly lower
Aβ burden compared with vehicle-treated male mice, but ABX-
treated female mice did not demonstrate a reduction in Aβ
burden compared with vehicle-treated female mice (Fig. 2 A).
We also observed trends of lower amyloid plaque size in ABX-
treated male compared with vehicle-treated male mice (Fig. S4).
Taken together, these data indicate that ABX-induced pertur-
bations in the microbiome are associated with significantly
lower amyloidosis only in male APPPS1-21 mice.
The morphology of plaque-localized microglia show
sex-specific characteristics in APPPS1-21 mice at the age of
7 wk
In view of earlier studies demonstrating microbiome-dependent
influences on microglial gene expression and morphological
phenotypes (Erny et al., 2015), we sought to evaluate the mor-
phological characteristics ofmicroglia in the brains of vehicle- or
ABX-treated APPPS1-21 mice. We evaluated plaque-localized
Dodiya et al. Journal of Experimental Medicine 1544
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Table 1. List of significantly different Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using PICRUSt analysis in fecal samples
Pathways Abundance mean FDR-P
22-d-old mice (n = 10/group)
M_Vehicle M_ABX
M_Vehicle and M_ABX
Bacterial toxins 13,235.5 6,249.4 0.000866
Lipopolysaccharide biosynthesis 49,150.4 13,221.2 0.000866
Oxidative phosphorylation 150,609.4 55,329.3 0.000809
Protein digestion and absorption 4,943 677.2 0.000866
F_Vehicle F_ABX
F_Vehicle and F_ABX
Bacterial invasion of epithelial cells 1.7 280.4 0.016666
Bacterial secretion system 76,012.7 2,6207.1 0.000365
Bacterial toxins 14,961.8 6,209.4 0.000365
Lipopolysaccharide biosynthesis 58,487.2 8,127.1 0.000365
Lipopolysaccharide biosynthesis proteins 73,421.5 13,334.1 0.000365
Primary immunodeficiency 6,215.7 3813 0.001623
Protein digestion and absorption 4,994.6 354.6 0.000599
Protein folding and associated processing 80,495.2 2,8776.3 0.000365
7-wk-old mice (n = 10/group)
M_Vehicle M_ABX
M_Vehicle vs. M_ABX
Bacterial chemotaxis 46,114.3 7,472.1 0.001933
Bacterial secretion system 102,269.1 59,364.3 0.006067
Bacterial toxins 21,094 13,546.8 0.009024
Primary immunodeficiency 8,583 4,712.8 0.002232
Protein folding and associated processing 115,193 64,080.4 0.006067
Secretion system 168,262.9 84,057.7 0.006067
Ubiquitin system 509.6 1,545.5 0.005581
F_Vehicle F_ABX
F_Vehicle vs. F_ABX
Bacterial chemotaxis 31,193 144,38.1 0.023303
Ubiquitin system 585.7 2,040.6 0.002061
M_ABX F_ABX
M_ABX vs. F_ABX
Bacterial chemotaxis 7,472.1 14,438.1 0.007826
Bacterial secretion system 59,364.3 106,765.7 0.006385
Bacterial toxins 13,546.8 20,489.3 0.012471
Lipopolysaccharide biosynthesis 50,195.1 82,159 0.007149
Lipopolysaccharide biosynthesis proteins 65,304.7 103,956.6 0.007149
Primary immunodeficiency 4,712.8 6,936.5 0.006385
Protein folding and associated processing 64,080.4 110,534.4 0.006385
Secretion system 84,057.7 156,112.4 0.006385
Significantly different KEGG pathways were analyzed by using PICRUSt analysis at both P22 (22-d-old) and 7 wk of age. The false discovery rate P (FDR-P) <
0.05 was selected for significance. Fecal bacterial relevant KEGG pathways are reported to understand the predicted functional pathways. F_ABX, ABX-treated
female mice; F_Vehicle, vehicle-treated female mice; M_ABX, ABX-treated male mice; M_Vehicle, vehicle-treated male mice. n = 10/group.
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microglia (0.02 mm2 area containing a 3D6+ Aβ plaque) in the
cerebral cortex using immunofluorescence staining with anti-
bodies raised to the microglial antigen, ionized calcium binding
adaptor molecule 1 (Iba1). High-magnification images containing
Iba1+ microglia around the 3D6+ Aβ plaque structures were
collected and analyzed by using ImageJ software. Microglial cell
body area and the total number of microglia were quantified
(Fig. 2 B). The total number of plaque-localized microglia
showed no significant differences with ABX-treatment or sex
(Fig. 2 B). In contrast, we observed a significantly reduced area
of microglial cell bodies in ABX-treated male mice compared
with vehicle-treated male mice. Notably, vehicle-treated female
mice showed reduced microglial cell body area compared with
vehicle-treated male mice. More importantly, ABX-treated fe-
male mice showed significantly larger cell body area compared
with vehicle-treated female mice (Fig. 2 B).
To assess the morphology of plaque-localized microglia, we
employed an Imaris software platform to generate 3D re-
constructions (Fig. 2 C). The total dendrite branch length and total
number of branch points of plaque-localized microglia were
evaluated in vehicle- or ABX-treated mice. ABX treatment re-
sulted in significantly longer dendritic branch lengths inmale but
not female mice compared with their vehicle-treated counter-
parts. Notably, vehicle-treated female mice showed shorter
dendritic branch lengths compared with vehicle-treated male
mice (Fig. 2 C, e). In addition, vehicle-treated femalemice showed
significantly lower dendritic branch points compared with
vehicle-treated male mice. However, ABX treatment resulted in a
higher number of dendritic branch points in male but not in fe-
male mice compared with their control counterparts (Fig. 2 C, f).
Collectively, these data indicate that in male mice an ABX-
perturbated microbiome is associated with lower numbers of
phagocytic, plaque-localized microglia, as defined by smaller cell
bodies, longer dendritic branch lengths, and increased dendritic
branches. On the other hand, femalemice exhibited a phagocytic
microglial phenotype as defined by larger cell bodies, shorter
branch lengths, and fewer branch points that are independent of
vehicle or ABX treatment.
ABX treatment results in sex-specific gene expression profiles
in the cerebral cortex of APPPS1-21 mice at the age of 7 wk
In addition to microglia morphology (Fig. 2, B and C), we also
investigated transcriptome profiles that might reflect relevant
functional outcomes. We purified total cortical RNA and then
hybridized these preparations to a NanoString MG550 chip
that harbors targets of microglia-specific transcripts and a pa-
nel of additional inflammation and phagocytosis-related genes
(Krasemann et al., 2017). Of 482 targets, 160 showed a significant
sex effect, while 57 showed a significant treatment effect, and
108 showed significant sex and treatment interactions. The
comparison of the gene patterns via K-means clustering of sig-
nificantly affected genes revealed four gene clusters (Fig. 3 A),
and a principal component analysis plot of these genes revealed
distinct sex-specific differences in ABX- versus vehicle-treated
APPPS1-21 mice (Fig. 3 B). Here, we observed marked differ-
ences in gene expression between control and ABX-treated male
mice, while the female mice did not show major changes be-
tween groups.
We extracted the genes from each cluster (Fig. 3 A) in order
to identify the effects of ABX treatment within sexes (Fig. 3 C).
Figure 1. ABX treatment results in microbiome changes in male and female APPPS1-21 mice (n = 10/group). (A) The PCoA plot at week 7 generated by
using weighted versions of the UniFrac distance metric. The two components explained 59.51% of the variance. (B and C) At week 7 also, both α diversity
values (species richness and evenness) were significantly lower in the ABX treatment group compared with the control (Faith’s phylogenetic diversity [B]: two-
way ANOVA, F[1,35] = 367.6, P < 0.0001; Pielou’s evenness [C]: two-way ANOVA, F[1,35] = 14.73, P = 0.0005). Sex or an interaction between sex and ABX
treatment showed no significant difference in either richness or evenness (P > 0.05). Post hoc comparisons showed reduced diversity in ABX-treated male
(Faith: P < 0.0001, Pielou: P = 0.049) and ABX-treated female (Faith: P < 0.0001, Pielou: P = 0.0462) mice compared with their vehicle-treated counterparts.
Data are mean ± SEM. *, P < 0.05; ****, P < 0.0001. n = 10/group. PCA1, principal coordinate 1; PCA2, principal coordinate 2.
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Table 2. ANCOM significant differences in fecal microbiota at week 7 (FDR-P < 0.05)
Higher in F_Vehicle Lower in F_Vehicle
M_Vehicle vs.
F_Vehicle
ESV NS p_Tenericutes; c_Mollicutes; o_RF39; f_; g_; s_
L7 clustered taxa NS NS
Higher in F_ABX Lower in F_ABX
M_ABX vs. F_ABX
ESV p_Verrucomicrobia;c_Verrucomicrobiae;f_Verrucomicrobiaceae;
g_Akkermansia;s_muciniphila
NS
L7 clustered taxa p_Firmicutes;c_Erysipelotrichi;f_Erysipelotrichaceae;g_Allobaculum;s_ NS
Higher in M_ABX Lower in M_ABX
M_Vehicle vs.
M_ABX
ESV p_Bacteroidetes; c_Bacteroidia; f_Bacteroidaceae; g_Bacteroides;
s_ovatus
p_Bacteroidetes; c_Bacteroidia; f_S24-7; g_; s_ (×8)
p_Firmicutes; c_Erysipelotrichi; f_Erysipelotrichaceae; g_; s_ p_Proteobacteria; c_Epsilonproteobacteria; f_Helicobacteraceae;
g_Helicobacter; s_
p_Actinobacteria; c_Actinobacteria; f_Bifidobacteriaceae;
g_Bifidobacterium
p_Bacteroidetes; c_Bacteroidia; f_Porphyromonadaceae;
g_Parabacteroides; s_
p_Firmicutes; c_Bacilli; f_Lactobacillaceae; g_Lactobacillus; s_
L7 clustered taxa p_Bacteroidetes; c_Bacteroidia; f_Bacteroidaceae; g_Bacteroides;
s_ovatus
p_Actinobacteria;c_Actinobacteria;f_Bifidobacteriaceae;
g_Bifidobacterium;_
p_Bacteroidetes;c_Bacteroidia;f_Porphyromonadaceae;
g_Parabacteroides;s_distasonis
p_Firmicutes;c_Bacilli;f_Lactobacillaceae;g_Lactobacillus;s_
p_Firmicutes;c_Erysipelotrichi;f_Erysipelotrichaceae;_;_ p_Firmicutes;c_Clostridia;o_Clostridiales;_;_;_
p_Firmicutes;c_Erysipelotrichi;f_Erysipelotrichaceae;g_;s_ p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_
p_Firmicutes;c_Clostridia;f_Ruminococcaceae;g_Ruminococcus;s_
p_Firmicutes;c_Erysipelotrichi;f_Erysipelotrichaceae;
g_Allobaculum;s_
p_Proteobacteria;c_Deltaproteobacteria;f_Desulfovibrionaceae;
g_Desulfovibrio;s_C21_c20
p_Proteobacteria;c_Epsilonproteobacteria;f_Helicobacteraceae;
g_Helicobacter;s_
Higher in M_ABX Lower in M_ABX
F_Vehicle vs.
F_ABX
ESV p_Bacteroidetes; c_Bacteroidia; f_Bacteroidaceae; g_Bacteroides;
s_uniformis
p_Bacteroidetes; c_Bacteroidia; f_S24-7; g_; s_ (×11)
p_Verrucomicrobia; c_Verrucomicrobiae; f_Verrucomicrobiaceae;
g_Akkermansia; s_muciniphila
p_Actinobacteria; c_Actinobacteria; f_Bifidobacteriaceae;
g_Bifidobacterium
p_Bacteroidetes; c_Bacteroidia; f_S24-7; g_; s_ p_Bacteroidetes; c_Bacteroidia; f_Porphyromonadaceae;
g_Parabacteroides; s_
p_Proteobacteria; c_Betaproteobacteria; f_Alcaligenaceae;
g_Sutterella; s_
p_Firmicutes; c_Bacilli; f_Lactobacillaceae; g_Lactobacillus; s_
p_Firmicutes; c_Erysipelotrichi; f_Erysipelotrichaceae
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Microglia switch from an "M0 (homeostatic molecular and
functional signature)" phenotype (Butovsky et al., 2014) to a
microglia neurodegenerative phenotype (MGnD) during the
course of aging and disease (Krasemann et al., 2017). We ob-
served that ABX-treated male mice exhibited increase in the
homeostatic microglial transcriptomic signature in clusters
1 and 3, including Mef2a, Junb, Bhlhe41, Fos, and Tnfrsf11a, and
decreased expression of MGnD genes, including Lgals3, C1qa,
C1qb, CD63, and Lag3 in clusters 2 and 4. Interestingly, ABX
treatment had opposite effects in male and female mice on eight
genes consisting of Sbf2, NRG1, Synj1, Map3k7, Ptgds, Sez6l, Gas6,
and Agpat3.
Ingenuity pathway analysis revealed that the TGFβ pathway
was a major upstream regulator predicted to be increased in
ABX-treated males (Fig. 3 D). Up-regulated genes in the pathway
included Il10ra, Fos, Csf1, Bmp4, and Bmp7 while the suppressed
genes included Lgals3 and Ccnd1. Quantitative PCR analysis of
miR-155, a microRNA that is induced in MGnD microglia,
showed a decrease in expression in male mice treated with ABX
compared with vehicle, while the female mice did not show a
significant difference between groups (Fig. 3 E). Taken together,
these results suggest that treatment of male APPPS1-21 mice
with ABX restores microglial homeostasis, likely via induction of
TGFβ signaling and several key transcriptional regulators of M0
microglia including Mef2a, Fos, and other homeostatic and anti-
inflammatory modulators such as Il10ra and Gas6.
Longer-term ABX treatment results in reduced Ab deposition
only in male APPPS1-21 mice
In studies presented in Fig. 4 A, we interpreted these results to
suggest that Aβ burden was selectively decreased in male mice
compared with female mice by ABX. The caveat of this inter-
pretation is that the Aβ burden in female mice treated with
vehicle was far too low to make an assessment of ABX-mediated
changes in Aβ burden. To circumvent this potential caveat, we
evaluated the impact of ABX onmale and female APPPS1-21 mice
at 3 mo of age. As expected, Aβ burden was elevated in vehicle-
treated, 3-mo-old male and female mice (Fig. 2 A and Fig. 4 A),
and more importantly, cortical Aβ burden was comparable be-
tween male and female mice. In 3-mo-old male APPPS1-21 mice,
ABX lead to a significant lowering of amyloid burden compared
with vehicle-treated male mice, but this was not the case in
female mice (Fig. 4 A).
We extended these latter analyses to characterize the mor-
phological phenotypes of plaque-localized microglia in male mice
at 3 mo of age. While the total number of plaque-localized mi-
croglia showed no significant differences with ABX treatment
(Fig. 4 B), the area of microglial cell bodies in ABX-treated male
mice was significantly reduced compared with vehicle-treated
male mice. Furthermore, plaque-localized microglial morphology
showed significantly longer dendritic branch lengths and in-
creased numbers of dendritic branch points in ABX-treated male
mice comparedwith vehicle-treatedmalemice (Fig. 4 B), similar to
the observations in 7-wk-old animals (Fig. 4 C). Collectively, ABX
leads to reductions in Aβ burden in male but not in female mice.
Fecal microbiota transplantation (FMT) from APPPS1-21 donor
into ABX-treated male mice reduces cecal enlargement and
restores fecal microbiome profiles
To confirm the causal role of the microbiome in Aβ amyloidosis
and gliosis, we performed FMT from age-matched APPPS1-21
male mice into our ABX-treated male mice every day from P25
till the time of cull (7 wk of age).
As above, cecal-weight analysis confirmed the effectiveness
of FMT in ABX-treated male mice (Fig. 5 A); compared with
ABX+vehicle–treated mice, ABX+FMT–treated mice showed
significantly lower cecum weight, thus suggesting recoloniza-
tion of the host (Fig. 5 A).
We then profiled the microbiome at 7 wk to confirm the ef-
fectiveness of the FMT protocol. The β diversity using un-
weighted UniFrac was significantly different between Tg-donor
and ABX+Vehicle–treatedmice and showed a clear separation on
a PCoA visualization. FMT resulted in a clear separation between
ABX+FMT–treated mice compared with ABX+Vehicle–treated
mice while Tg-donor and FMT-gavaged ABX-treated mice were
clustered very closely, thus suggesting that FMT-treatment in
ABX-treatedmice showed similar microbiome profiles as the Tg-
donor mice (Fig. 5 B). Unweighted β diversity was significantly
different although with a low effect size, while weighted was not
significant, indicating that lower diversity taxa had a larger
Table 2. ANCOM significant differences in fecal microbiota at week 7 (FDR-P < 0.05) (Continued)
Higher in F_Vehicle Lower in F_Vehicle
L7 clustered taxa p_Bacteroidetes;c_Bacteroidia;f_Bacteroidaceae;g_Bacteroides;
s_uniformis
p_Actinobacteria;c_Actinobacteria;f_Bifidobacteriaceae;
g_Bifidobacterium;_
p_Bacteroidetes;c_Bacteroidia;f_Porphyromonadaceae;
g_Parabacteroides;s_distasonis
p_Firmicutes;c_Clostridia;o_Clostridiales;_;_;_
p_Firmicutes;c_Erysipelotrichi;f_Erysipelotrichaceae;_;_ p_Firmicutes;c_Clostridia;f_Ruminococcaceae;g_Ruminococcus;
s_
p_Verrucomicrobia;c_Verrucomicrobiae;f_Verrucomicrobiaceae;
g_Akkermansia;s_muciniphila
p_Proteobacteria;c_Epsilonproteobacteria;f_Helicobacteraceae;
g_Helicobacter;s_
To determine the taxa that described the most variance between groups, ANCOM analyses of 16S rRNA sequencing data at the DADA2-inferred ESV level
(taxonomy assigned via Greengenes) and clustered species levels were performed between vehicle- or ABX-treated groups in a sex-dependent manner. F_ABX,
ABX-treated female mice; F_Vehicle, vehicle-treated female mice; M_ABX, ABX-treated male mice; M_Vehicle, vehicle-treated male mice. n = 10/group.
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effect on differentiating the microbial profiles. α diversity in-
dices showed significantly lower richness and evenness in
ABX+Vehicle–treated mice compared with the Tg-donor while
ABX+FMT mice showed no significant differences compared
with the Tg-donor (Fig. 5, C and D).
ANCOM comparison at the ESV and species levels showed
significant differences between both Tg-donor and ABX+
FMT–treated groups and between ABX+FMT–treated and
ABX+Vehicle–treated groups but with far more differences ob-
served in the latter pairing, as expected. Tg-donor groups only
Figure 2. Reductions in Ab pathology and altered plaque-
localized microglial phenotypes are only observed in ABX-
treated male APPPS1-21 mice. (A) Representative images of
Aβ plaque burden in the cortex of vehicle (a and c) and ABX-
treated (b and d) in 7-wk-old APPPS1-21 mice using anti-Aβ
monoclonal antibody, 3D6. (a and b) Male vehicle vs. ABX,
respectively; (c and d) female vehicle vs. ABX, respectively. (e)
Quantification of plaque burden in vehicle- and ABX-treated
APPPS1-21 mice using threshold-limited particle analysis of
3D6+-positive staining from six sections per case and ex-
pressed relative to the total cortical area of each slice. Aβ
burden analysis revealed a significant effect of ABX (two-way
ANOVA: F[1, 36] = 10.58, P = 0.0025) and an interaction (F[1, 36] =
9.145, P = 0.0046) while sex showed no significant effect
(F[1, 36] = 1.76, P = 1929). (B) Representative images of mi-
croglial cells using Iba1 antibody. No differences in total Iba1-
positive cells were observed in vehicle versus ABX treatment
irrespective of sex (male: a, b, and e; female: c, d, and e; two-
way ANOVA—ABX treatment: F[1, 36] = 0.036, P = 0.85; or
sex: F[1,36] = 0.19, P = 0.668; or an interaction between ABX
treatment and sex: F[1,36] = 0.131, P = 0.718). In contrast, the
area of Iba1-positive cell bodies was significantly reduced
in ABX treated male mice (b and f) but not in females (d and
f; two-way ANOVA—ABX treatment: F[1, 36] = 14.77, P =
0.0005; sex: F[1, 36] = 4.97, P = 0.0321; and an interaction:
F[1, 36] = 142.2, P < 0.0001). Control male mice showed
larger cell bodies compared with control female mice (P <
0.0001). ABX treatment resulted in significantly smaller
cell bodies in males (P < 0.0001) and larger cell bodies in
females (P < 0.0001) compared with their respective
controls. (C) Imaris 3D reconstruction showed signifi-
cantly different microglia morphology characteristics in
males (a and b) compared with females (c and d) after ABX
treatment (microglial branch length—two-way ANOVA:
F[1, 36] = 70.77, P < 0.0001; microglial branch end points:
F[1, 36] = 61.24, P < 0.0001), with sex (microglial branch
length: F[1, 36] = 91.42, P < 0.0001; microglial branch end
points: F[1, 36] = 75.38, P < 0.0001), and an interaction
(microglial branch length: F[1, 36] = 29.63, P < 0.0001;
microglial branch end points: F[1, 36] = 22.73, P < 0.0001).
Vehicle-treated male mice showed significantly longer
branch lengths (a; quantified in e, P = 0.029) and number
of branch points (a; quantified in f, P = 0.04) compared
with vehicle-treated females (c). ABX treatment resulted
in significantly longer branch lengths (b; quantified in e,
P < 0.0001) and increased numbers of branch points (b;
quantified in f, P < 0.0001) in male mice. Scale bars in A
(a–d), B (a–d), and C (a–d) represent 500 µm, 10 µm, and
10 µm, respectively. Data are mean ± SEM. *, P < 0.05;
***, P < 0.001; ****, P < 0.0001; n = 10/group.
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Figure 3. ABX treatment restores TGFb signaling and the microglial homeostatic signature in the cerebral cortex of APPPS1-21 male mice.
(A) K-means clustering of 246 significantly affected genes in RNA samples extracted from cortex tissue lysates from vehicle and Abx-treated APPPS1-21 male
and female mice by using NanoString analysis. Vertical lanes are biological replicates per treatment and sex. (B) A principal component analysis (PCA) plot
based on significantly affected genes between treatment and sex groups. (C) Student’s t tests within each sex and between ABX-treated and -untreated mice
were conducted on the genes within each cluster from A to reveal significantly affected genes based on ABX treatment (P < 0.05). Genes in red are up-
regulated, and genes in blue are down-regulated. (D) Ingenuity pathway analysis shows up-regulation of the TGFβ pathway–related molecules in tissue from
ABX-treated male mice. (E) Quantitative PCR analysis of ABX-treated male and female mice revealed a significant decrease (P < 0.05) of miR-155 expression in
ABX-treated male but not female mice. Data are mean ± SEM. *, P < 0.05. n = 6/group. Ctr, control.
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differed from ABX+FMT–treated mice in two Bacteroidales S24-7
family member ESVs and a Bacteroides species. At the ESV level,
the ABX+FMT–treated group compared with ABX+Vehicle–
treated group had a significantly higher abundance of several
members of the Bacteroidales order, including Bacteroides,
Prevotella, and S24-7, while ABX+Vehicle–treated mice showed
a higher abundance of a single S24-7 ESV. At the L7 level, a
number of varying taxa were found, but only those higher in
Figure 4. Reduced Ab pathology and altered microglial phenotypes in cerebral cortex of ABX-treated male APPPS1-21 mice at 3 mo of age.
(A) Representative images of Aβ plaque burden in the vehicle (a and c) and ABX (b and d) treated male (a and b) and female (c and d) mice using 3D6 antibody
(e). Aβ burden was significantly lower in ABX-treated male mice (n = 8) compared with vehicle-treated male mice (P = 0.0116) while female mice showed no
significant differences in Aβ burden (P > 0.05) with ABX treatment (two-way ANOVA—ABX treatment: F[1, 23] = 5.419, P = 0.0291; sex: F[1, 23] = 7.173, P = 0.0134,
and an interaction: F[1, 23] = 5.707, P = 0.0255). (B) Representative images (a–d) of Iba1-positive microglial cells in close proximity to 3D6+ immunostained
Aβ plaque (<0.07-mm radial distance from plaque) in 3-mo-old male mice. (e) Cell count analysis showed no significant differences between vehicle- or ABX-
treated male mice; (unpaired Student’s t test: t[12] = 1.661, P = 0.1225). ABX treatment (c and d) resulted in smaller cell bodies compared with vehicle-treated
(a and b) male mice (f; unpaired Student’s t test: t[12] = 4.573, P = 0.0006). Imaris 3D reconstruction (g and h) showed significantly different microglial char-
acteristics between vehicle- and ABX-treated male APPPS1 mice. Branch length/microglia (g) showed significantly higher branch length in ABX-treated mice
(unpaired Student’s t test: t[12] = 3.096, P < 0.0093). Moreover, ABX-treated mice also showed significantly higher numbers of branch points per plaque localized
microglia (h; unpaired Student’s t test: t[12] = 4.178, P < 0.0013). Scale bars in A (a, b, c, and d) and B (a, b, c, and d) represent 1,000 µm and 10 µm, respectively.
Data are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Male_vehicle: n = 6. Male_ABX: n = 8. Female_vehicle: n = 6. Female_ABX: n = 6.
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abundance in the ABX+FMT–treated group were significant
(Table 3). Taken together, ABX+Vehicle treatment resulted in
reduced diversity and altered microbiome, whereas the FMT
protocol in ABX-treated mice resulted in the restoration of
diversity and a microbiome profile more similar to the
transgenic donor.
FMT from APPPS1-21 Tg-donor partially restores Ab plaque
burden and microglial morphologies in ABX-treated male mice
at the age of 7 wk
Having demonstrated that the microbiota in 7-wk-old mice
subject to the ABX+FMT protocol is similar to the Tg-donor, we
then asked whether this would translate to a restoration in
plaque burden and microglial phenotypes. The ABX+FMT–
treated group showed significantly higher Aβ burden and larger
plaque size in the cortex compared with the ABX+Vehicle–
treated group (Fig. 6 A). Moreover, The ABX+FMT–treated
group showed significantly larger microglial cell body area
compared with ABX+Vehicle–treated group (Fig. 6 B), but no
changes in total microglia numbers were observed (Fig. 6 B).
Finally, microglia showed significant shortening of dendritic
branch lengths and reductions of dendritic branch points in the
ABX+FMT–treated group compared with the ABX+Vehicle–
treated group (Fig. 6 C). These data suggest that FMT from
Tg-donor into ABX-treated male mice partially restored Aβ
amyloidosis and microglia morphology.
Discussion
Dysregulation in the microbiome-gut-brain axis is now emerg-
ing for a variety of neurological diseases, including Parkinson’s
disease and AD and developmental and psychiatric conditions.
We have explored the impact of the microbiome in Tg mouse
models of Aβ amyloidosis. Extending our earlier findings using
the APPSWE/PS1ΔE9 mouse model showing a significant impact of
ABX-mediated alterations of the microbiome on Aβ pathology
and microglial phenotypes (Minter et al., 2016, 2017), we have
examined these parameters in another well-established APPPS1-
21 mouse model and now offer several important insights. First,
we demonstrated that long-term ABX treatment of male
APPPS1-21 mice results in distinct alterations in peripheral cy-
tokines/chemokines, changes in the composition of the fecal
microbiome, and a significant reduction in Aβ deposits. In con-
trast, ABX-treated female mice exhibited a greater abundance of
bacteria and predicted metabolic pathways that are considered
pro-inflammatory, higher levels of plasma pro-inflammatory
cytokines/chemokines, and no apparent effects on the levels of
Aβ deposits compared with vehicle-treated animals. Second, we
Figure 5. FMT reverts ABX-associated changes in the gut microbiome (n = 9/group). (A) Cecum weights from vehicle- or FMT-treated ABX-treated male
mice. FMT introduced into ABX-treated APPPS1-21 male mice lead to reduced cecumweight (unpaired Student’s t test: t[16] = 4.372, P = 0.0005). (B) PCoA plot
generated by using unweighted versions of the UniFrac distance metric. The two components explained 44.98% of the variance. FMT-treated ABX-treated
male mice showed no clear separation compared with the donor fecal microbiome while vehicle-treated ABX-treated male mice showed a clear separation
compared with the other two groups. The α diversity was measured by using Pielou’s evenness (Pielou_E; C) and Faith's phylogenetic diversity (Faith_pd; D)
indices. FMT treatment restored the microbiome diversity as measured by both Faith’s phylogenetic diversity (one-way ANOVA: F[2,16] = 32.91, P < 0.0001) and
Pielou’s evenness (one-way ANOVA: F[2,16] = 18.7, P < 0.0001). Data are mean ± SEM. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. n = 9/group. PCA1, principal
coordinate 1; PCA2, principal coordinate 2.
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show that ABX-treated male mice exhibited alterations in mi-
croglial morphologies similar to those observed in GF wild-type
mice (Erny et al., 2015) and transcriptional signatures that are
consistent with activation of the TGFβ signaling pathway that is
a hallmark of M0 (homeostatic) microglia (Butovsky et al.,
2014). In sharp contrast, the microglia in ABX-treated female
mice exhibited retracted processes and larger cell bodies that
closely mimicked that observed in MGnD microglia, findings
supported by transcriptional readouts. Finally, transplants of
feces from age-matched APPPS1-21 male donor mice into long-
term ABX-treated male mice resulted in the restoration of mi-
crobiota profiles, elevated MGnD-type microglia, and partial
restoration in Aβ deposition, thus confirming a causal relation-
ship between the gut microbiome and AD-associated inflam-
mation and Aβ pathology in this model.
While it has been reported that the microbiome can modulate
disease phenotypes in a sex-specific manner (Markle et al., 2013;
Yurkovetskiy et al., 2013; Sampson et al., 2016), our current
studies are the first to report sex-specific alterations in AD-
related phenotypes by the gut microbiome using a mouse
model of Aβ amyloidosis. Our results are consistent with pub-
lished studies that included GF and ABX-treated wild-type mice,
wherein themicrobiome exerts sex-specific effects onmicroglial
maturation leading to altered immune responses to environ-
mental stimuli such as the bacterial endotoxin (Erny et al., 2015;
Hanamsagar et al., 2017; Thion et al., 2018). Taken together with
our current findings, it is highly probable that the microbiome
can have a significant impact on the maturation and function of
brain immune cells and in a sex-specific manner.
The mechanism(s) underlying “clearance” of Aβ aggregates/
oligomers/plaques are largely silent. In this regard, our micro-
glial transcriptome studies indicate that microglia in vehicle-
treated mice exhibit an MGnD signature and that ABX-treated
male mice exhibit an M0 homeostatic signature, leading to the
suggestion that ABX alters the cellular response of microglia to
Aβ plaques (or oligomeric Aβ species). Alternatively, and a
model that we favor, is that at the time of culling, microglia
exhibit an M0 signature because these cells have been clearing
plaques/oligomers throughout the lifetime of the animal and
there is very little left to be cleared. Future studies using real-
time, simultaneous two-photon confocal imaging of GFP-labeled
microglia and plaque intercalating dyes during the mouse life-
time will be essential to resolving this important lacuna in our
understanding of the role and mechanism(s) by which microglia
in ABX-treated animals mediate clearance of Aβ in the mouse
models.
Peripheral inflammation plays a major role in central in-
flammation (Perry et al., 2007; Wendeln et al., 2018). We
observed relatively lower expression of pro-inflammatory
cytokines/chemokines, including cluster of differentiation
30 (CD30), CD40, CCL11 (Eotaxin1), IL-1B, IL-2, IL-3, IL-17A,
LIX (CXC5), RANTES (CCL5), and SCF, and higher anti-
inflammatories, such as IL10 in ABX-treated male mice. In
contrast, ABX-treated female mice showed relatively higher
levels of pro-inflammatory cytokines (CCL11, IL-1B, IL-2, IL-3,
IL-5, IL-9, IL-17, LIX, and SCF) compared with ABX-treated
male mice. In this regard, microbiome-derived metabolites
can influence peripheral cytokine production (Wikoff et al.,
Table 3. ANCOM significant differences in fecal microbiota at week 7 (FDR P < 0.05)
Higher in ABX+FMT Lower in ABX+FMT
Tg-donor vs. ABX+FMT
ESV p_Bacteroidetes; c_Bacteroidia; f_S24-7; g_ (×2)
L7 clustered taxa p_Bacteroidetes;c_Bacteroidia;f_Bacteroidaceae;g_Bacteroides;s_
ABX+Vehicle vs. ABX+FMT
ESV p_Bacteroidetes; c_Bacteroidia; f_S24-7; g_ (×2) p_Bacteroidetes; c_Bacteroidia; f_S24-7; g_; s_
p_Bacteroidetes; c_Bacteroidia; f_Prevotellaceae; g_Prevotella; s_
p_Bacteroidetes; c_Bacteroidia; f_Bacteroidaceae; g_Bacteroides
p_Bacteroidetes; c_Bacteroidia; f_Bacteroidaceae; g_Bacteroides; s_
L7 clustered taxa p_Bacteroidetes;c_Bacteroidia;f_Bacteroidaceae;g_Bacteroides;s_
p_Bacteroidetes;c_Bacteroidia;f_Bacteroidaceae;g_Bacteroides;s_g_Odoribacter;s_
p_Bacteroidetes;c_Bacteroidia;f_[Paraprevotellaceae];g_Paraprevotella;s_
p_Deferribacteres;c_Deferribacteres;f_Deferribacteraceae;g_Mucispirillum;
s_schaedleri
p_Firmicutes;c_Clostridia;f_Ruminococcaceae;g_Ruminococcus;s_
p_Proteobacteria;c_Alphaproteobacteria;o_RF32;f_;g_;s_
p_Proteobacteria;c_Deltaproteobacteria;f_Desulfovibrionaceae;g_;s_
To determine the taxa that described the most variance between groups, ANCOM analyses of 16S rRNA sequencing data at the DADA2-inferred ESV level
(taxonomy assigned via Greengenes) and clustered species levels were performed between vehicle-treated or FMT-treated ABX-treated male mice at the age
of 7 wk. ABX+FMT, FMT (from Tg-donor)-gavaged ABX-treated male mice; ABX+Vehicle, vehicle-gavaged ABX-treated male mice.
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2009). Microbiota can also influence the relative populations
and function of subsets of immune cells (Ivanov et al., 2009;
Dorrestein et al., 2014) modulating mucosal immune re-
sponses (Mazmanian et al., 2005; Kamada et al., 2013) and
systemic immunity (Belkaid and Naik, 2013). It is possible
that altered peripheral inflammation due to microbiome
perturbations in our model could impact brain inflammation
that ultimately affects microglia. Future investigations of the
effect of plasma samples on microglial Aβ phagocytosis from
our mice will allow us to address the role of peripheral
inflammation.
Our microbiome data reveal no significant differences com-
paring sexes in vehicle and ABX treatment at P22, but the mi-
crobiome profiles at the time of culling (7 wk of age) represented
Figure 6. FMT from APPPS1-21 male mice to ABX-treated APPPS1-21 male mice resulted in restoration of Ab pathology and microglial phenotypes.
(A) Representative images of Aβ plaque burden in the cortex of vehicle- (a) and FMT-treated ABX-treated mice (b) using 3D6 antibody. (c) Quantification of
plaque burden in vehicle- and FMT-treated ABX-treated male mice. Aβ burden was significantly higher in ABX+FMT–treated mice compared with
ABX+vehicle–treated mice (two-tailed Student’s t test: t[15] = 2.209, P = 0.0431). (d) Aβ particle size was also significantly higher in ABX+FMT–treated mice
compared with ABX+vehicle–treated mice (two-tailed Student’s t test: t[15] = 2.355, P = 0.0326). (B) Representative images of Iba1-positive microglial cells (a
and b). (c) Cell count analysis showed no significant differences between ABX+vehicle–treated mice (a) versus ABX+FMT–treated mice (b; unpaired Student’s
t test: t[16] = 0.3026, P = 0.7661). However, FMT resulted in larger cell bodies compared with vehicle-treated ABX-treated male mice (d; unpaired Student’s
t test: t[16] = 4.968, P = 0.0001). (C) Imaris 3D reconstruction showed significantly different microglial characteristics between vehicle-treated (a) and FMT-
treated (b) ABX-treated male mice. Branch length/microglia (c) showed significantly lower branch length in ABX+FMT–treated mice (unpaired Student’s t test:
t[16] = 6.823, P < 0.0001). Moreover, ABX+FMT–treated mice showed significantly lower numbers of branch points per plaque-localized microglia (d; unpaired
Student’s t test: t[16] = 6.876, P < 0.0001). Scale bars in A (a and b), B (a and b), and C (a and b) represent 1,000 µm, 10 µm, and 10 µm, respectively. Data are
mean ± SEM. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. n = 8–9/group.
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a significant effect of sex in ABX-treated mice. Importantly, we
observed ABX-treated female mice showed a greater abundance
of Allobaculum (s_unknown) and Akkermansia (s_muciniphila), as
well as higher levels of peripheral pro-inflammatory cytokines
and phagocytic microglia and no changes in Aβ amyloidosis.
Certain Allobaculum and Akkermansia species are known mucin
degraders, a greater proportion of which could lead to a decrease
the mucin-layer thickness, which may not only result in greater
inflammatory activation but also could increase the likelihood of
translocation of bacteria or bacterial metabolites from the gut to
circulation. We are not able to prove this with the current data,
but it remains a compelling hypothesis to test. Increased mi-
crobial or metabolite translocation can increase endotoxin levels
in the systemic circulation, affecting peripheral and central in-
flammation as reported (de Punder and Pruimboom, 2015).
Akkermansia has previously been associated with various neu-
rodegenerative disorders (Keshavarzian et al., 2015; Jangi et al.,
2016; Berer et al., 2017; Engen et al., 2017). Similarly,
Allobaculum has been negatively correlated with anti-
inflammatory genes Forkhead box protein P3 (FOXP3), IL-10,
and intestinal barrier proteins ZO-1 and occludin (Lee et al.,
2015). In the FMT study, a large number of organisms of order
Bacteroidales were found to be higher in ABX+FMT–treated
mice, possibly driving a restoration in pathology. Significant
changes in Akkermansia and Allobaculum were not observed via
ANCOM in this cohort. Other taxa that were increased in
ABX+FMT–treated mice also may have contributed to pathology;
in particular Mucispirillum schaedleri, a possible pathobiont
(Nguyen et al., 2015), was in a higher abundance in the FMT
treatment group. It thus remains unclear if changes in diversity,
changes in overall bacterial communities, or changes in men-
tioned individual genera result in observed sex-specific immune
and pathological outcomes in our model. Future transplantation
studies involving full FMT or selected bacteria in GF mice will
help resolve these issues.
Finally, we acknowledge several limitations of our studies.
First, we used long-term ABX treatment to evaluate microbiome
perturbations and effects on amyloidosis and microglial activity
and our FMT protocol to prove causation was performed si-
multaneously with diluted ABX. It is plausible that diluted ABX
in drinking water could have an impact on FMT efficiency that
affects our final outcomes of amyloidosis and microglia mor-
phology measures. Future work using established short-term
(P14–P21) ABX gavage will allow us to address this concern in
our model. Second, our NanoString studies were aimed at in-
vestigating microglial inflammatory gene profiles, but because
the RNA was prepared from the entire cerebral cortex our data
could certainly be influenced by the expression of the identified
genes in other cell types represented in the cortex. Future
transcriptomic studies of purified microglia and other cortical
cell types in our experimental paradigm will be essential to
clarify the underlying cellular and physiological basis underly-
ing the observations reported herein.
In conclusion, our findings are fully consistent with the
conclusion that ABX-mediated perturbations of the microbiome
have selective, sex-specific influences on brain Aβ amyloidosis
and microglial homeostasis.
Materials and methods
Animal housing and handling
APPPS1-21 mice were maintained on a C57BL6Cj background
and obtained from M. Jucker (University of Tubingen, Tu-
bingen, Germany). Mice were housed in sterile micro-isolator
cage and fed ad libitum on standard chow. All animal ex-
perimental procedures were performed in accordance with
the approved Animal Care and Use Protocols by the Institu-
tional Animal Care and Use Committee at the University of
Chicago.
ABX treatment
Pups receiving the ABX were gastric gavaged (200 µl ABX by
using animal feeding needles; catalog number 7901; Cadence)
with established ABX (Stefka et al., 2014; 4 mg/ml kanamy-
cin, Sigma-Aldrich K4000-5g; 0.35 mg/ml gentamicin,
Sigma-Aldrich G1914-250mg; 8,500 U/ml colistin, Sigma-
Aldrich C4461-1g; 2.15 mg/ml metronidazole, Sigma-Aldrich
M1547-25g; 0.45 mg/ml vancomycin, Sigma-Aldrich V2002-
1g) in autoclaved water from P14 to P21 followed by an ad
libitum access to freshly prepared 1:50 diluted ABX water
until the time of sacrifice. During 7 d of postnatal ABX ga-
vage, all mice were transferred to a new sterile cage after
each gavage to avoid microbial contamination from accu-
mulated fecal pellets in the cages. Parents from the same
cage as pups receiving ABX treatment were euthanized after
weaning the pups and were not used for any breeding or
future experiments. Water with ABX was changed every
5–6 d.
Fecal pellet collection
To evaluate the microbiome profile after high-dose ABX treat-
ment (P14–P21), fresh fecal pellet samples from each pup were
collected in sterile 1.5-ml centrifuge tubes at P22 and stored in
−80°C. Fresh fecal pellets were also collected at the time of
sacrifice and immediately frozen and stored at −80°C until the
time of bacterial DNA extraction.
Necropsy and tissue harvesting
The necropsy was performed according to procedures ap-
proved by Animal Care and Use Protocols. Briefly, a mixture of
ketamine and xylazine was introduced i.p., and after confir-
mation of deep anesthesia, the heart was accessed through
abdominal surgery, and blood was collected from the right
ventricle by using a 25-gauge needle and stored in buffered
sodium citrate blood collection tubes (catalog number 366393;
BD Vacutainer) on ice. After the blood collection, the de-
scending aorta was clamped, and mice were perfused by using
cold saline (pH 7.4) for 3 min. Brains were then excised and
dissected into two hemispheres (one hemisphere was post-
fixed with 4% paraformaldehyde, and the other was frozen for
RNA extraction). Cecum was collected and weighed after
careful removal from the small and large intestine. After the
necropsy, plasma was separated from blood cells by centrif-
ugation at 2,000 rpm for 10 min at 4°C by using a Beck-
man Coulter centrifuge and stored at −80 for the cytokine
measurements.
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Microbiome analysis
The V4 region of the bacterial 16S rRNA gene was amplified by
using the Earth Microbiome Project primer set (515f-806r).
Each 25-ml PCR reaction contained 12.5 ml of AccuStart II PCR
ToughMix (Quantabio), 1 µl of 5 µM forward primer, 1 µl of
5 µM reverse primer, 9.5 µl of water, and 1 µl of DNA ex-
traction. The PCR program was 94°C for 3 min to denature the
DNA, with 35 cycles at 94°C for 45 s, 50°C for 60 s, 72°C for
90 s, and then a final 72°C step. Amplification was quantified
by using PicoGreen (Invitrogen), and each sample was pooled
at 70 ng per sample. Pools were cleaned by using Agencourt
AMPure XP beads (Beckman Coulter), and the clean pools
were combined. This final pool was quantified and sent to the
Environmental Sample Preparation and Sequencing Facility at
Argonne National Laboratory for sequencing on an Illumina
Miseq by using v3 chemistry following the Earth Microbiome
Project protocol.
Raw 16S reads were demultiplexed, chimera and phiX
filtered through the QIIME2 pipeline, and denoised with
DADA2 (Callahan et al., 2016). The resulting representative
sequences were aligned and masked with MAFFT (Katoh
et al., 2002). A phylogenetic tree was constructed via Fast-
Tree 2 (Price et al., 2010). Samples were subsequently clus-
tered and taxonomically classified into operational taxonomic
units (OTUs) with QIIME2 by using the Greengenes 99%
database (DeSantis et al., 2006). Diversity metrics were
calculated after rarefying reads at a depth of 10,000 se-
quences. β diversity was calculated as unweighted and
weighted UniFrac distances. Faith’s phylogenetic diversity
and Pielou’s evenness were used to measure α diversity.
ESVs are reported with Greengenes-assigned taxonomy and
species level clustered to OTUs by the QIIME2 Bayesian
classifier. Differences in relative abundances were calcu-
lated via ANCOM (Mandal et al., 2015) and considered sig-
nificant at the P < 0.05 level. Correlations of metadata with
OTU abundances were calculated as Spearman rank corre-
lations with raw P values determined via bootstrapping
(1,000 permutations). All reported P values are false dis-
covery rate–corrected for multiple comparisons.
Cytokine antibody array
At the time of necropsy, blood samples were collected from
the right ventricles of anesthetized mice. Plasma was sepa-
rated by using 10-min centrifugation at 2,000 rpm at 4°C.
Plasma (50 µl) from 10 mice in each treatment group was
pooled into one sample and diluted 1:1 (vol/vol) in blocking
buffer per the manufacturer’s suggestion. Diluted plasma was
then probed for the cytokine profile by using the Mouse Cy-
tokine Antibody Array 3.1 Kit according to the manufacturer’s
protocol (RayBiotech). Briefly, membranes were blocked with
a blocking buffer, and then 1 ml of diluted serum sample per
group was added to each membrane and incubated at 4°C
overnight. The next day, membranes were washed and incu-
bated in biotinylated antibody cocktail at room temperature
for 1.5 h. The membranes were then incubated with HRP-
streptavidin concentrate at room temperature for 2 h, and
cytokine presence was detected by chemiluminescence. Films
of array dots were scanned and converted to TIFF format to
import into ImageJ software. Densitometry was performed for
each circle by using ImageJ software. The background was
subtracted by using blank optical density, and data were
normalized against controls among membranes. These data
were then transformed into Log2 to calculate Log2fold change
values. Heatmaps were generated using R software for Log2-
fold change data.
Immunocytochemistry
To perform immunofluorescence staining, a full series was
selected for Aβ (3D6, 1:10,000) staining, and a half series
was selected for microglia (Iba1, 1:500) marker. Briefly,
cryoprotectant-stored brain tissue sections (40-µm thick)
were washed with dilution media for 60 min (10 min/wash,
six washes). After blocking with serum solution for 1 h, tissue
sections were incubated in primary antibodies for overnight
in a 4°C refrigerator. The next day, the sections were brought
to room temperature. Tissue sections were washed with di-
lution media for 60 min (10 min/wash, six washes) and in-
cubated in secondary fluorescence antibodies (DAM488 and
DARab594; Invitrogen; 1:500) for 1 h at room temperature in
the dark. Sections were then washed with dilution media
again and incubated in DAPI (Invitrogen, 1:10,000) for
counterstaining. After three washes (10 min each) of Tris-
buffered saline, the tissue samples were then mounted on
glass slides and coverslipped by using Fluoromount aqueous
mounting medium (catalog number F4680, Sigma-Aldrich).
3D6+ Aβ plaque images were captured by using Pannoramic
SCAN BF plus FL Optimum slide scanner (PerkinElmer/
3DHistech). Microglia images were captured by using a laser
confocal microscope (SP6, Leica) under 40 × 1.5 (for cell
counts and diameter measures) or 60 × 2 (for 3D recon-
struction) magnification.
Ab load (3D6 counting) analysis
Six sections of cortical cerebrum at an equidistance of
240 µm were selected for 3D6+ Aβ plaque analysis. Total
plaque number and Aβ area fraction were calculated by using
the Fiji ImageJ software (ImageJ 1.51n, National Institutes of
Health). In particular, images were normalized, and an au-
tomatic thresholding based on the entropy of the histogram
(“MaxEntropy”) was used to identify the plaques. Pictures
were converted into 8-bit format, followed by binary con-
version and the “fill holes” and “watershed” algorithm were
applied. Finally, plaque number, plaque area, and region of
interest were calculated by using the “analyze particles”
plugin of ImageJ. The Aβ area fraction (Aβ burden) was de-
termined by dividing the total plaque area by the area of the
cerebral cortex (region of interest).
Microglia morphology characterization
Cell counting and cell body area measurements were collected
by using National Institutes of Health ImageJ software. In
brief, z-stack images of individual plaques from 40-µm-thick
sections were obtained under 40 × 1.5 magnification (oil im-
mersion lens) with 0.35-µm-step increments in the z plane.
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A total of four to five immunofluorescence images per case
containing 3D stacks of 3D6 (Aβ plaque), Iba1 (microglia),
and DAPI (nucleus) were collected and imported into
ImageJ. After individual channels were separated, the Iba1
staining containing z-stack was processed with maximum-
intensity projections. These maximum-intensity projection
images were used to measure the number of microglia cells
and cell body area. The total area for the region of interest
and number of microglia cells around the plaque were
quantified manually in each section. Iba1+ individual cell
body or cell overlaps were confirmed with DAPI containing
the z-stack. The average number of microglia cells/plaque per
0.02-µm2 area was collected for each case. By using freehand
selection, each microglial cell body was outlined to measure
the cell body area. The average cell body area was collected
for each case.
Three-dimensional reconstruction by using Imaris (Bit-
plane) was performed to measure microglia cell branch
lengths and the number of branch point parameters as pub-
lished previously (Minter et al., 2017). Sections co-labeled
with 3D6 (Aβ plaque), Iba1 (microglia), and DAPI (nucleus)
were prepared as above. The z-stack images of individual
plaques from 40-µm-thick sections were obtained under 60×
magnification with 0.35-µm-step increments in the z plane.
These z-stack images were then analyzed by using Imaris
software. By using the filament tool, all microglial dendrite-
like processes were mapped and recorded. The surface tool
was used to establish the realm of the Aβ plaque. Quantifi-
cation of average dendrite length and the total number of
dendrite branch points was collected by using an in-built
analysis program. A total of four Aβ plaque-containing mi-
croenvironments were analyzed per mouse.
FMT
Control age-matched APPPS1-21 male donor mice were used
to collect the fresh fecal pellets. Donor mice (n = 4) were
housed under specific pathogen-free conditions in a separate
cage from experimental groups with ad libitum food and
water access. Fresh fecal pellets from individual donor mice
were collected and immediately mixed in sterile water (5 mg
fecal content dissolved in 1 ml sterile water). The fecal slurry
supernatant was collected after allowing the suspension to
settle down by using gravity for 5 min. Each postnatally
treated high-dose ABX-recipient mouse in the ABX+FMT–
treated group received 200 µl of freshly prepared fecal slurry
from the age-matched donor mouse by gastric gavage daily
starting at on P25 until the time of sacrifice simultaneously
with low-dose ABX in the water (original experimental de-
sign). The ABX+Vehicle–treated group received 200 µl of
sterile water in a similar fashion to nullify the everyday ga-
vage effect.
RNA isolation and NanoString analysis
Total RNA was isolated from the cortex of 7-wk-old mice by
using TRIzol reagent (Ambion) followed by RNeasy Micro
clean-up (QIAGEN) procedure according to the manu-
facturer’s protocol. All RNAs were analyzed on an Agilent
Bioanalyzer for quality assessment. 100 ng of total RNA was
used in NanoString analysis by using MG550 Chip, which
contains 400 unique and enriched microglial genes and 150
inflammation- and phagocytosis-related genes (Butovsky et al.,
2014). NanoString data were analyzed by using nSolver soft-
ware. RNA counts for target genes were normalized to the
mean of housekeeping genes (Cltc, Gapdh, Gusb, Hprt, Pgk1,
and Tubb5) to account for differences in the RNA content. The
value of the highest negative control on the chip was used to
set the cutoff, and the fold changes were calculated by com-
paring the ABX-treated group to the respective vehicle-
treated group.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism
software. Multiple-group comparisons were performed by
using two-way ANOVA, and group differences were evaluated
by using the post hoc Bonferroni multiple-comparison test.
For three-group comparisons (Tg_donor versus ABX+Vehicle
versus ABX+FMT), one-way ANOVA was performed followed
by Bonferroni multiple-comparison post hoc analysis. Two-
group comparisons (ABX+Vehicle and ABX+FMT) were per-
formed by using the two-tailed unpaired Student’s t test.
Significance was accepted at values of P < 0.05. NanoString
data (RNA counts) were normalized by the geometric mean of
six housekeeping genes: Cltc, Gapdh, Gusb, Hprt, Pgk1, and
Tubb5. A cutoff was introduced at the value of the highest
negative control present on the chip. A two-way ANOVA was
used to identify significantly affected genes (P < 0.05) among
four treatment/sex groups and Student’s t tests were used to
identify ABX treatment effects. Heatmaps and clustering were
generated in R by using heatmap.2 from the gplots package
and the prcomp from the stats package. For clustering,
z-scores were calculated by using the mean expression of
biological replicates per treatment group and sex and then
subsequently clustered by using K-means. A scree plot was
used to assess the number of clusters.
Online supplemental material
Fig. S1 presents Western blot results by using human APP)-
specific 6E10 antibody to detect steady-state levels of full-
length human APP (APP-FL), β-carboxyl-terminal fragment
(β-CTF), and Aβ peptides comparing both APPPS1-21 and
APPSWE/PS1ΔE9 mice. Fig. S2 presents microbial diversity data
at P22 and cecal weight analysis at 7-wk of age. Fig. S3 pres-
ents immunoblots and heatmap analysis of fold-changes in
levels of plasma cytokines/chemokines from vehicle- or ABX-
treated mice in a sex-dependent manner. Fig. S4 shows Aβ
plaque size analysis in the cerebral cortex of 7-wk-old
APPPS1-21 mice. Table S1 presents ANCOM significant dif-
ferences in fecal microbiota at P22.
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